It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13

Jefferies Downgrades XOMA, Ltd. (XOMA) to Hold

Jefferies downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Hold with a price target of $1.00 (from $7.00).

Analyst Biren Amin commented, "XOMA announced that gevokizumab missed on the primary endpoint on time to first exacerbation in EYEGUARD-B for Behcets uveitis as a result of... More

Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to Neutral

Ladenburg Thalmann downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Neutral with a price target of $1.00 (from $6.00).

For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.

Shares of XOMA, Ltd. closed at $4.40 yesterday.

RBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector Perform

RBC Capital downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Sector Perform with a price target of $2.00 (from $8.00).

Analyst Adnan Butt said, "Phase III Behcets study was higher risk but going forward is likely to create uncertainty around Phase III... More

Cowen Downgrades XOMA, Ltd. (XOMA) to Market Perform

Cowen downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Market Perform after the company announced that gevo's EYEGUARD-B trial in Behçets uveitis did not meet its primary endpoint. The firm said the gevo's viability is now in question.

Analsyt Phil Nadeau... More

Unusual 11 Mid-Day Movers 7/22: (SLTD) (LPCN) (BZUN) Higher; (XOMA) (ANGI) (CZR) Lower

XOMA (Nasdaq: XOMA) 74.3% LOWER; announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.

Solar3D, Inc. (Nasdaq: SLTD) 24.4% HIGHER; announced preliminary results for the second quarter ended June 30, 2015. Revenue for the 2015 second quarter is expected to exceed $11.0 million. This represents an increase... More

Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to Neutral

Piper Jaffray downgraded XOMA, Ltd. (NASDAQ: XOMA) from Overweight to Neutral.

For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.

Shares of XOMA, Ltd. closed at $4.40 yesterday.

Pre-Open Stock Movers 07/22: (ISRG) (THOR) (EYES) Higher; (XOMA) (ILMN) (AAPL) Lower (more...)

XOMA (NASDAQ: XOMA) 79% LOWER; Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular exacerbation.

Intuitive Surgical (NASDAQ: ISRG) 12% HIGHER; reported Q2 EPS of $4.57, $0.59 better than the analyst estimate of $3.98. Revenue for the quarter came in at $586.1 million versus the consensus estimate of $566.86... More

XOMA (XOMA) Slammed 70% as Trading Resumes

XOMA (NASDAQ: XOMA) has resumed trading and is down 67% after announcing the Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular exacerbation.

XOMA (XOMA) to Resume Trading at 8:30 AM

XOMA (NASDAQ: XOMA) to Resume Trading at 8:30 AM

XOMA (XOMA) Announced Phase 3 EYEGUARD-B Missed Primary Objective

XOMA (NASDAQ: XOMA) announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.

"Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations... More

XOMA (XOMA) halted with news pending

XOMA (NASDAQ: XOMA) halted with news pending.